ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Scope & Guideline

Pioneering Innovations in Infectious Disease Research

Introduction

Delve into the academic richness of ANTIMICROBIAL AGENTS AND CHEMOTHERAPY with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN0066-4804
PublisherAMER SOC MICROBIOLOGY
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1963 to 1970, from 1972 to 2024
AbbreviationANTIMICROB AGENTS CH / Antimicrob. Agents Chemother.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address1752 N ST NW, WASHINGTON, DC 20036-2904

Aims and Scopes

The journal 'Antimicrobial Agents and Chemotherapy' focuses on advancing the understanding of antimicrobial agents and their applications in treating infectious diseases. It emphasizes research that spans the microbiological, pharmacological, and clinical dimensions, providing a platform for innovative studies that address contemporary challenges in antimicrobial therapy.
  1. Antimicrobial Resistance Mechanisms:
    Research on the mechanisms by which bacteria and fungi develop resistance to various antimicrobial agents, including β-lactams, fluoroquinolones, and antifungals.
  2. Clinical Pharmacokinetics and Pharmacodynamics:
    Studies that analyze the pharmacokinetics and pharmacodynamics of antimicrobial agents, aiming to optimize dosing regimens and improve therapeutic outcomes.
  3. Novel Antimicrobial Agents:
    Development and evaluation of new antimicrobial compounds, including novel antibiotics, antivirals, and antifungals, targeting resistant pathogens.
  4. In Vitro and In Vivo Efficacy Studies:
    Evaluation of antimicrobial efficacy through laboratory and clinical studies, including animal models, to assess the effectiveness of new and existing therapies.
  5. Epidemiological Surveillance:
    Investigations into the epidemiology of infectious diseases, including the prevalence and spread of resistant strains in various populations.
  6. Innovative Therapeutic Approaches:
    Research on combination therapies, phage therapy, and other novel strategies to enhance the efficacy of existing antimicrobial treatments.
Recent publications reflect dynamic shifts in the research landscape of antimicrobial agents, highlighting emerging themes that are gaining increased attention. These trends indicate the evolving nature of infectious disease challenges and the response of the scientific community.
  1. Antimicrobial Stewardship:
    Growing focus on antimicrobial stewardship programs aimed at optimizing the use of antimicrobials to combat resistance and improve patient outcomes.
  2. Phage Therapy:
    Increased interest in bacteriophage therapy as a viable alternative or adjunct to antibiotics, particularly against multidrug-resistant bacteria.
  3. Machine Learning and AI in Drug Development:
    Application of machine learning and artificial intelligence techniques to predict antimicrobial efficacy, optimize dosing regimens, and identify novel drug candidates.
  4. Global Surveillance of Resistance Patterns:
    Enhanced efforts in global surveillance studies to track antimicrobial resistance patterns, particularly in response to the COVID-19 pandemic.
  5. Pharmacogenomics:
    Emerging research into pharmacogenomic factors affecting antimicrobial therapy, tailoring treatments based on individual genetic profiles.
  6. Combination Therapy Approaches:
    A trend towards exploring combination therapies that synergize multiple agents to enhance efficacy against resistant pathogens.

Declining or Waning

While the journal continues to cover a wide range of topics in antimicrobial research, certain areas have seen a decline in publication frequency or interest. This may indicate shifting research priorities or the saturation of previously hot topics.
  1. Traditional Antibiotics:
    Research focusing on the efficacy of traditional antibiotics has diminished as the field shifts towards exploring novel agents and combination therapies.
  2. Single-Agent Studies:
    There has been a noticeable reduction in studies investigating the effectiveness of single-agent treatments, as the focus moves towards combination therapies to combat resistance.
  3. Non-Pharmacological Interventions:
    Studies examining non-pharmacological interventions (e.g., infection control measures) in antimicrobial therapy have decreased, likely due to a greater emphasis on drug development.
  4. Antifungal Resistance Mechanisms:
    While antifungal resistance remains a concern, the volume of research specifically addressing resistance mechanisms has seen a relative decline compared to the surge in studies on bacterial resistance.

Similar Journals

EXPERT OPINION ON INVESTIGATIONAL DRUGS

Unlocking the Potential of Emerging Therapies
Publisher: TAYLOR & FRANCIS LTDISSN: 1354-3784Frequency: 12 issues/year

Expert Opinion on Investigational Drugs, published by Taylor & Francis Ltd, is a premier journal dedicated to the dissemination of high-quality, peer-reviewed research in the fields of pharmacology and medicine. As an integral part of the scientific community since its inception in 1994, this journal has established itself as a leading source of insightful analysis and expert commentary on emerging drug therapies, providing invaluable resources for researchers, clinicians, and healthcare professionals. With an impressive impact factor and ranking in the top quartile across multiple pharmacological categories, it remains a vital platform for discussing innovative drug developments and their clinical applications. Though it operates on a subscription basis, Expert Opinion on Investigational Drugs is crucial for anyone involved in pharmacological research and the drug development process, positioning itself at the forefront of medical advancements and offering critical insights into the rapid evolution of investigational therapies.

Infectious Diseases and Therapy

Fostering collaboration for impactful healthcare advancements.
Publisher: SPRINGER LONDON LTDISSN: 2193-8229Frequency: 4 issues/year

Infectious Diseases and Therapy is a premier scholarly journal published by Springer London Ltd, dedicated to advancing the understanding of infectious diseases through rigorous research and evidence-based therapy. With an esteemed Q1 ranking in both the Infectious Diseases and Microbiology (medical) categories, this journal is a vital resource for researchers, healthcare professionals, and students aiming to stay at the forefront of developments within the field. Launched in 2012, it has embraced an Open Access model, ensuring that groundbreaking studies and critical reviews are accessible to a global audience. Operating from its office in London, the journal encourages the dissemination of innovative therapies and diagnostic methods, fostering collaboration and knowledge sharing among the scientific community. In a landscape where infectious diseases pose significant health challenges, Infectious Diseases and Therapy stands as an essential platform for impactful research that can lead to improved healthcare outcomes worldwide.

Infection and Chemotherapy

Fostering Dialogues for a Healthier Tomorrow
Publisher: KOREAN SOC ANTIMICROBIAL THERAPYISSN: 2093-2340Frequency: 4 issues/year

Infection and Chemotherapy, an esteemed journal published by the Korean Society of Antimicrobial Therapy, focuses on the dynamic fields of infectious diseases and pharmacology. With an ISSN of 2093-2340 and an E-ISSN of 2092-6448, this peer-reviewed, open-access journal has been providing a crucial platform for research dissemination since 2008. Based in South Korea, it boasts a significant impact in the academic community, as evidenced by its Q2 ranking in both Infectious Diseases and Pharmacology categories for 2023. It holds a Scopus rank of 64 out of 272 in Pharmacology and 98 out of 344 in Infectious Diseases, showcasing its prominence and the quality of research it publishes. With a focus on advancing scientific knowledge, Infection and Chemotherapy is committed to fostering essential dialogues among researchers, clinicians, and students, making it a vital resource for those engaged in the fight against infectious diseases and the development of effective therapeutic protocols.

JAC-Antimicrobial Resistance

Unraveling Mechanisms, Impacting Lives
Publisher: OXFORD UNIV PRESSISSN: Frequency: 4 issues/year

JAC-Antimicrobial Resistance, published by Oxford University Press, is a pioneering open-access journal that has been contributing to the vital discourse on antimicrobial resistance since its inception in 2019. With an E-ISSN of 2632-1823, the journal operates out of the United Kingdom and is dedicated to advancing our understanding of antimicrobial resistance mechanisms, impacts, and solutions across a variety of related fields including Immunology, Infectious Diseases, and Microbiology. The journal currently ranks in the Q2 category for these disciplines, highlighting its growing impact and relevance within the academic community. Researchers, practitioners, and students alike will find a treasure trove of high-quality, peer-reviewed articles that are freely accessible, aligning with contemporary trends in scientific publishing. As the world grapples with the rising threat of antimicrobial resistance, JAC-Antimicrobial Resistance stands as an essential resource for those seeking to stay at the forefront of this critical field.

Journal of Global Antimicrobial Resistance

Exploring the forefront of antimicrobial resistance research.
Publisher: ELSEVIER SCI LTDISSN: 2213-7165Frequency: 4 issues/year

The Journal of Global Antimicrobial Resistance, published by Elsevier Scientific Ltd, is a premier open access journal dedicated to addressing the critical issue of antimicrobial resistance on a global scale. Established in 2013 and significantly gaining traction as an open access platform since 2020, this journal serves as an essential resource for researchers, healthcare professionals, and policy makers invested in immunology, microbiology, and associated fields. With an impressive impact factor reflected through its consistent ranking in the Q2 category across multiple disciplines, including Microbiology and Immunology – where it ranks #29 out of 140 in Medical Microbiology – the journal ensures high-quality peer-reviewed articles that push the boundaries of current knowledge and practice. By offering a global perspective on research trends and public health implications, the Journal of Global Antimicrobial Resistance plays a pivotal role in advancing the scientific discourse necessary to combat the rising tide of antimicrobial resistance worldwide.

Pathogens

Innovating Solutions for Tomorrow's Health Challenges
Publisher: MDPIISSN: Frequency: 12 issues/year

Pathogens is a leading open-access journal published by MDPI since 2012, dedicated to advancing the understanding of infectious agents and their interactions with hosts in the fields of immunology, microbiology, and molecular biology. Based in Switzerland, this journal plays a crucial role in disseminating high-quality research that spans from fundamental studies of pathogen biology to the implications for global health and disease management. With a commendable impact factor and prestigious Q2 rankings across multiple categories—including Immunology and Microbiology—Pathogens ensures visibility and accessibility for groundbreaking findings. The journal embraces the ethos of open access, allowing researchers, professionals, and students to access critical research anytime, facilitating a collaborative and innovative academic environment. By bridging the gap between research and application, Pathogens is instrumental in shaping the future of infectious disease research and management.

CANCER CHEMOTHERAPY AND PHARMACOLOGY

Fostering collaboration in the fight against cancer through science.
Publisher: SPRINGERISSN: 0344-5704Frequency: 12 issues/year

Cancer Chemotherapy and Pharmacology, published by Springer, is a leading peer-reviewed journal that plays a crucial role in the field of cancer research and drug therapy. With an ISSN of 0344-5704 and an E-ISSN of 1432-0843, this journal has been a cornerstone of oncology and pharmacology research since its inception in 1978, with continued relevance through to 2024. The journal holds a commendable Q2 ranking in categories such as Cancer Research, Oncology, and Pharmacology (medical), while achieving an elite Q1 status in Toxicology, reflecting its high-impact contributions to the scientific community. Researchers and professionals benefit from access to cutting-edge studies, insightful reviews, and innovative methodologies, making it a vital resource for anyone working at the intersection of pharmacology and oncology. Although not an open-access journal, Cancer Chemotherapy and Pharmacology remains highly accessible through institutional subscriptions, ensuring it reaches a broad audience dedicated to advancing cancer treatment and patient care.

JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS

Advancing Veterinary Care Through Innovative Research
Publisher: WILEYISSN: 0140-7783Frequency: 6 issues/year

JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS is a crucial publication in the field of veterinary medicine, dedicated to advancing knowledge and practices related to pharmacology and therapeutic interventions in animals. Published by WILEY, this peer-reviewed journal has been a reliable source of innovative research since its inception in 1978, and it continues to play an integral role in shaping veterinary pharmacology through its commitment to high-quality scientific discourse. With an impact factor reflective of its robust academic standing, the journal is categorized in the Q3 quartile for Pharmacology and Q2 for Veterinary (miscellaneous) as of 2023, highlighting its relevance and significance within these domains. It is indexed in Scopus with commendable rankings, particularly in General Veterinary, where it ranks #45 out of 194, placing it in the 77th percentile. This journal not only offers a platform for original research articles but also caters to the dissemination of practical applications and reviews that are essential for veterinarians, researchers, and students alike in enhancing animal health and welfare. Although not an open-access publication, its contributions remain accessible to those engaged in the veterinary sciences through institutional subscriptions. The journal's enduring legacy and forward-looking approach make it a vital resource for anyone interested in veterinary therapeutics and pharmacology.

Reviews and Research in Medical Microbiology

Delivering High-Impact Research for Healthcare Professionals
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 2770-3150Frequency: 4 issues/year

Reviews and Research in Medical Microbiology is a premier academic journal published by LIPPINCOTT WILLIAMS & WILKINS, focusing on groundbreaking research and comprehensive reviews that advance the understanding of medical microbiology. With an ISSN of 2770-3150 and an E-ISSN of 2770-3169, this journal serves as an essential resource for researchers, healthcare professionals, and students dedicated to the study of pathogens, infectious diseases, and microbial mechanisms affecting health. While the journal currently does not offer open access, its rigorous peer-review process ensures that only high-quality, impactful research is disseminated to the scientific community. The journal aims to bridge gaps in knowledge by presenting cutting-edge studies that explore novel therapeutic strategies, diagnostic methods, and the evolving landscape of microbial resistance. Nestled in the heart of Philadelphia, this journal proudly contributes to the advancement of medical microbiology and is an indispensable platform for the publication of critical findings that shape clinical practices and research trajectories in the field.

ACS Infectious Diseases

Exploring Innovations in Infectious Disease Solutions
Publisher: AMER CHEMICAL SOCISSN: 2373-8227Frequency: 12 issues/year

ACS Infectious Diseases is a premier journal in the field of infectious diseases, published by the American Chemical Society. With an impressive Impact Factor that places it in the Q1 category for Infectious Diseases in 2023, the journal serves as an essential resource for researchers, healthcare professionals, and students dedicated to the study of infectious agents and their impact on public health. Established in 2015, the journal is committed to publishing cutting-edge research that enhances our understanding of infectious diseases and fosters the development of innovative interventions. Although not an open access journal, it provides a platform for high-quality research that influences policies and practices in the field. With an address located at 1155 16TH ST, NW, WASHINGTON, DC 20036, ACS Infectious Diseases is an authoritative voice in advancing the science and practice of infectious disease management.